The immunofluorescent stainings revealed an increase in CD8+ T cells, macrophages and NK cells under DMF/ECP-combination therapy and hinting a shift towards a more pro-inflammatory tumor microenvironment under DMF/ECP-combination therapy (Fig. 5). The gene discussed is CD8A; the disease is neoplasm.